Bispecific Antibody Market Share

North American Market Forecast

The North American region is projected to hold over 35% share of the global bispecific antibody market by the end of 2037, due to rising demand for targeted and personalized therapies. For the previous eight years, personalized medicines have been responsible for at least twenty-five percent of new drug approvals in the United States. Moreover, in 2022, twelve personalized medications have been approved, accounting for about 34 percent of all freshly approved therapeutic molecular entities. This customization enables the development of therapies that are tailored to the molecular profile of a patient’s tumor potentially increasing treatment efficacy and reducing adverse effects. Hence, it is set to drive the expansion of the bispecific antibody market in the region.

APAC Market Statistics

The Asia Pacific bispecific antibody market is estimated to be the 2^nd largest, with a share of about 24% by the end of 2037. Rising government initiatives for the treatment of rare diseases. In March 2021, the government announced the National Policy for Rare Diseases (NPRD), 2021 in India, to help patients with rare diseases. The government intends to provide financial assistance of up to USD 61, 146 to individuals suffering from any category of Rare Diseases. Moreover, there is also a provision for proving the treatment in any of the Centre of Excellence falls under NPRD-2021. Such initiatives focused on improving patient access to bispecific antibody treatments for rare diseases. This may include insurance coverage and reimbursement of these therapies, ensuring that patients can afford and access these innovative treatments.